Lincoln Pharmaceuticals Reports FY26 Results, Recommends 18% Dividend

Lincoln Pharmaceuticals Reports FY26 Results, Recommends 18% Dividend​

Lincoln Pharmaceuticals Limited announced its financial results for the year ending March 31, 2026, today, detailing a robust performance marked by growth across its key segments. The company recommended a dividend of 18% on its equity shares for the fiscal year 2025-26.

The company reported a consolidated net profit of Rs. 87.89 crore for the fiscal year 2025-26, marking a 6.74% year-on-year increase compared to Rs. 82.35 crore in FY25. Revenue from Operations for FY26 reached Rs. 704.48 crore, showing a growth of 9.10% Y-o-Y. Furthermore, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at Rs. 131.14 crore, reflecting a 5.78% growth year-on-year. Earnings Per Share (EPS) for FY26 was reported at Rs. 43.88 per share.

Financial Performance Overview​

The company's financial performance demonstrated sustained growth across both the standalone and consolidated results.

The following table summarizes the key annual financial highlights for the company:


For the fourth quarter of FY26, the company reported a consolidated net profit of Rs. 11.63 crore, compared to Rs. 11.57 crore in Q4FY25, representing a 0.52% Y-o-Y growth. Revenue from Operations for Q4FY26 stood at Rs. 183.08 crore, marking a 13.50% Y-o-Y increase.

Strategic Outlook and Market Standing​

Management reaffirmed a commitment to expansion, noting that the company is targeting a total revenue of Rs. 1,000 crore within the next three years. This ambition is supported by a broader strategy aiming for a 15-18% annual growth rate. This targeted growth is expected to be fueled by robust performance across the cardiac, diabetic, dermatology, and ENT segments.

The company’s strong market positioning was validated recently when CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL A I' ratings on the bank facilities, a rating issued on January 9.

In terms of institutional ownership, Foreign Institutional Investors (FIIs) increased their stake in the company to 5.20% as of March 31, 2026, up from 5.00% in the previous fiscal year. Domestic Institutional Investors (DIIs) held a stake of 1.08% as of the same date.

Operations and Commitment​

Mr. Munjal Patel, Director of Lincoln Pharmaceuticals Ltd, noted that the strong conclusion to FY26 was driven by robust demand and improved operational efficiencies. He highlighted the company's continued focus on strengthening its product portfolio, expanding both domestic and international presence, and making investments in research and manufacturing capabilities.

The company currently operates a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, which complies with stringent international quality norms and is certified by EUGMP, TGA, and WHO-GMP. Lincoln Pharmaceuticals Limited has a strong product portfolio of over 1,700 registered products, with an additional 700 formulations currently in development across 15 therapeutic areas. The company continues to expand its global reach, exporting to over 60 countries and aiming to expand its footprint to 90 countries over the next few years.

LINCOLN Stock Price Movement​

On Wednesday, Lincoln Pharmaceuticals Limited shares edged higher, rallying 1.68% to settle at ₹758.15. The equity enjoyed strong buying interest, trading on a robust volume of 123,783 shares, and managing to hit its 52-week high of ₹770.